KILPEST INDIA LTD.

3B BlackBio Dx Ltd has announced the closure of its trading window for directors, designated persons, and their immediate relatives. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will be closed effective July 1, 2026, and will reopen 48 hours after the public announcement of the unaudited financial results for the quarter ending June 30, 2026. The specific date for the board meeting to approve these results will be communicated later.

Dhirendra Dubey has acquired 1000 equity shares of 3B BlackBio Dx Ltd (formerly Kilpest India Limited) on June 24, 2026, through an open market transaction. This acquisition represents a minor increase of 0.011% in his shareholding. Prior to this transaction, Dubey held 7,24,098 shares, representing 8.44% of the total share capital. Post-acquisition, his total holding increased to 7,25,098 shares, accounting for 8.45% of the company's total equity. The total equity share capital of the company remains unchanged at Rs 8,58,26,700.

Dhirendra Dubey, a promoter of 3B BlackBio Dx Limited (formerly Kilpest India Limited), has acquired 1000 equity shares of the company on June 24, 2026. The acquisition was made through the open market. Prior to this transaction, Mr. Dubey held 7,24,098 shares, representing 8.44% of the total share capital. After the acquisition, his holding increased to 7,25,098 shares, constituting 8.45% of the total share capital. The total equity share capital of the company remains at Rs 8,58,26,700.

3B BlackBio Dx Ltd's board approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. They recommended a final dividend of ₹5.00 per equity share (50% of face value of ₹10 each) for FY26, subject to shareholder approval. The board also appointed M/s Ali Jain & Sharma as Internal Auditors for FY26-27. Baheti & Company issued unmodified audit opinions on the financial results.

3B BlackBio Dx Ltd announced audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The Board recommended a final dividend of 50% (₹5.00 per share). Revenue from operations for FY26 stood at ₹9727.50 Lakhs compared to ₹9052.97 Lakhs in FY25. The Board also approved the appointment of M/s Ali Jain & Sharma as Internal Auditors for FY27.

3B BlackBio Dx Ltd's board approved and recorded the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The board recommended a final dividend of 50%, i.e., ₹5.00 per equity share of ₹10 each, subject to shareholder approval. M/s Ali Jain & Sharma, Chartered Accountants, Bhopal, were appointed as Internal Auditor for FY 2026-27. The company reported revenue from operations of ₹9727.50 lakhs and a profit after tax of ₹4931.69 lakhs for the year ended March 31, 2026.

3B Blackbio Dx Ltd has scheduled a Board of Directors meeting on May 29, 2026, to consider and approve the audited financial results (standalone and consolidated) for the quarter/financial year ended March 31, 2026. The board will also discuss the recommendation of a dividend, if any, for the financial year ended March 31, 2026. The trading window remains closed from April 1, 2026, and will end 48 hours after the results are announced.

3B BlackBio Dx Limited announced that its equity shares have been admitted for trading on the National Stock Exchange of India Limited (NSE) with effect from April 20, 2026. This admission is in accordance with NSE Circular Ref. No. NSE/CML/73797 dated April 17, 2026. This development will enhance the liquidity and accessibility of the company's shares for investors on a broader trading platform.

In a disclosure under Regulation 31(4) of SEBI (SAST) Regulations, 2011, Mr. Nikhil Kuber Dubey, Promoter of 3B BlackBio Dx Ltd, has declared that neither he nor the Promoter & Promoter Group along with persons acting in concert of the company have made any encumbrance or pledge of shares directly or indirectly during the financial year ended 31st March 2026. This disclosure was made for the financial year ended on March 31, 2026.

3B BlackBio Dx Ltd has announced the closure of its trading window in accordance with the SEBI (Prohibition of Insider Trading) Regulations 2015. The closure is effective from 1st April, 2026 until 48 hours after the Audited Financial Results for the financial year ending on 31st March, 2026 are submitted to the Stock Exchange. The date of the Board Meeting to approve the Audited Financial Results will be informed in due course.